Dr. Reddys Laboratories Ltd.

Dr Reddy's Laboratories is expecting to launch 25 products in the US market in the current financial year (FY21). The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year.

Besides, the drug maker is also working on various biosimilar products, including, the Rituximab Phase III trial is progressing as per plan. And, in parallel, it is working on multiple other biosimilar products, which are at different stage of development.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.